Business Context and Reporting Period
This Form 8-K is filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc.) with a report date of January 8, 2015. The filing discloses the entry into a material definitive agreement regarding the potential sale of the company's equity stake in Ruthigen, Inc.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only specific financial value disclosed relates to the transaction:
- Asset Value: 2 million shares of Ruthigen, Inc. common stock.
- Agreed Purchase Price: $2.75 per share.
- Total Aggregate Value: $5,500,000.
Material Changes and Transaction Details
On January 8, 2015, Oculus entered into a Securities Purchase Agreement with two investors ("Buyers"). Key terms include:
- Standstill Period: Oculus agreed not to market, offer, or sell the Ruthigen shares to anyone other than the Buyers for 60 calendar days.
- Trigger Event: The Buyers irrevocably agreed to purchase all Ruthigen shares if a trigger event occurs during the Standstill Period. A trigger event is defined as the closing of a merger, consolidation, or sale of assets of Ruthigen, or the entry into a definitive agreement for such a transaction.
- Approvals: The transaction was approved by Ruthigen and Dawson James Securities, Inc., in accordance with the Separation Agreement dated August 2, 2013.
Guidance, Risks, and Contingencies
The filing contains forward-looking statements regarding the company's intentions and the planned spin-off or future events. Management notes that actual outcomes may differ materially due to risks and uncertainties. The sale of the Ruthigen shares is contingent upon the occurrence of a specific trigger event (merger or sale of Ruthigen) within the 60-day standstill period. The filing explicitly states it does not constitute an offer to sell securities and that any offer will be made only via a prospectus.
Investor Verification Checklist
- Verify the full text of the Securities Purchase Agreement filed as Exhibit 10.1 for complete terms and conditions.
- Confirm the current status of Ruthigen, Inc. and whether any merger or sale discussions are active.
- Review the Separation Agreement dated August 2, 2013, to understand the historical relationship and constraints between Oculus and Ruthigen.
- Check subsequent filings to determine if the trigger event occurred within the 60-day standstill period.